TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00645411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell culture-derived influenza subunit vaccine (cTIV)
Description: One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Egg derived influenza subunit vaccine (eTIV)
Description: One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell culture-derived influenza subunit vaccine (cTIV)
Description: Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Egg derived influenza subunit vaccine (eTIV)
Description: Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.
Study: NCT04645849

Intervention type: BIOLOGICAL
Intervention: Immunomonitoring
Description: 16 patients will be recruited at the end of treatment: an immunoprofiling analysis will be performed out of a blood sample about 1 month, 5 months and 9 months after treatment.~8 patients will be recruited at diagnosis: a immune profile analysis will be performed before the start of treatment. This will give comparative values for the immune system cells and molecules.

Intervention type: BIOLOGICAL
Intervention: Immunomonitoring
Description: 16 patients will be recruited at the end of treatment: an immunoprofiling analysis will be performed out of a blood sample about 1 month, 5 months and 9 months after treatment.~8 patients will be recruited at diagnosis: a immune profile analysis will be performed before the start of treatment. This will give comparative values for the immune system cells and molecules.
Study: NCT03560206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family SWaP intervention
Description: The Family Sodium Watcher Program (Family SWaP) proposed in this study incorporates the use of a unique electronic salt monitoring device that easily measures salt content in food-the major source of sodium. The intervention is designed to improve adherence to a sodium restricted diet by both patients and family caregivers through education and strategies for gradual taste adaptation to low salt foods. The Family SWaP intervention (6 weekly 45-minute sessions followed by 5 bi-weekly booster sessions) will be delivered remotely using a video-conferencing program on an iPad tablet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
Study: NCT02843100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Exclusive Enteral Nutrition
Description: Two weeks of Exclusive Enteral Nutrition with Modulen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crohn's Disease Exclusion Diet
Description: a limited whole food diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partial Enteral Nutrition
Description: 25-50% of Energy from formula
Study: NCT03399656

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Avmacol tablets
Description: The active components of Avmacol® are ground broccoli seeds that provide glucoraphanin and freeze-dried broccoli sprouts that provide a stabilized form of the enzyme myrosinase, which converts glucoraphanin to sulforaphane.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Avmacol tablets
Description: The active components of Avmacol® are ground broccoli seeds that provide glucoraphanin and freeze-dried broccoli sprouts that provide a stabilized form of the enzyme myrosinase, which converts glucoraphanin to sulforaphane.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Description: MCC 90M Emcocel

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: MCC 90M Emcocel
Study: NCT01642758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium 2,2 dimethylbutyrate
Description: Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
Study: NCT04274803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid, 20% Intravenous Emulsion
Description: intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy of antiphospholipis syndrome
Description: the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
Study: NCT03362229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixation
Description: A well reduced medial malleolus fracture will undergo internal fixation, guided by the surgeon's skill and expertise

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-fixation
Description: A well reduced medial malleolus fracture will be left without fixation
Study: NCT04149678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine
Study: NCT00290498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Arm A: Cyclophosphamide 300 mg/m\^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Arm A: Cyclophosphamide 300 mg/m\^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Arm A: Doxorubicin 50 mg/m\^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Arm A: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.~Arm B: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Arm B: Cytarabine 3 g/m\^2 by vein over 2 hours every 12 hours X 4 doses on days 3 \& 4, cycle 2 and alternating cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
Study: NCT02273713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine
Study: NCT01703065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given orally once a day
Study: NCT02641522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Single infusion of siltuximab (11 mg/kg)
Study: NCT01046240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: Palonosetron 3 mg administered SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 3 mg administered SC or IV
Study: NCT01290900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXL104
Description: IV Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXL104
Description: IV Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: IV Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Infusion
Description: IV Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: IV Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Description: IV Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Tablet (1)
Study: NCT04129710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 conventional infusion on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 conventional infusion on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 conventional infusion on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 250 mg/m2 over 3 hours on day3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 250 mg/m2 over 3 hours on day3
Study: NCT01183728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cells (MSV)
Description: Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
Study: NCT01567254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guided imaginary
Description: Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: music ONLY
Description: music. It will be equal in length to the auditory guided imagery disk
Study: NCT03293706

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHO Control 1 and 2 Glucose
Description: mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHO Control 1 and 2 Glucose
Description: mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 1 Slowly Digested
Description: mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 2 Digestion Resistant
Description: mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 3 Low Sugar
Description: mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 4 Maltodextrin
Description: mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
Study: NCT01816516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Babies
Description: Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).~The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expanded Food and Nutrition Education Program
Description: Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
Study: NCT00461851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given on day 1 to an AUC of 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
Study: NCT04018391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped care for nonadherence and depression
Description: * Problem Solving for Depression and Adherence: A 6-session adherence and depression intervention based on a culturally adapted LifeSteps and Problem Solving Therapy for Depression.~* Stepped Care Assessment for Antidepressant Treatment: If a participant's depression score remains above threshold in Session 6, the study interventionist will refer the participant to a Research Mental Health Nurse for a psychopharmacological assessment to prescribe an antidepressant to augment Problem Solving for Depression and Adherence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced Usual Care: A combination of 1) clinic-provided adherence counseling, 2) access to providers trained in the World Health Organization Mental Health Gap Intervention Guide (mhGAP), 3) a letter to the participant's medical provider detailing the depression diagnosis, 4) access to the treatment components of the TENDAI intervention at no cost, after the participant has completed their 12-month follow-up assessment.
Study: NCT00365872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell (DC) Injections
Description: * DCs (10\^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.~* One additional DC injection was given before surgery to assess DC migration~* Patients were assigned to one of three cohorts:~Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation was delivered 5 days per week (Monday-Friday).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete Resection - Surgery for tumor removal
Description: Tumors were surgically resected 3-6 weeks after the completion of EBRT.
Study: NCT01602627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 inhibitor AUY922
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03998345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 609A
Description: 609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
Study: NCT00303290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg Interferon Alpha 2b (Peg Intron)
Description: 4.5 micrograms/kg once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C (cytosine arabinoside)
Description: 10 mg under the skin daily
Study: NCT01090167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
Study: NCT01226602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6140
Description: P2Y12 receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00483431

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MK7

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MK7

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MK7

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MK7

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MK7

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MK7
Study: NCT01711931

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of everolimus-eluting bioresorbable vascular scaffold stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of everolimus-eluting stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of biolimus-eluting stents
Study: NCT00669240

Intervention type: DRUG
Intervention: Varenicline
Description: According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
Study: NCT04087551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Developing the list of items for BRFES
Description: The finalized list of items will be discussed by two researchers who will combine similar items generated by the two focus groups to complete the Balance Recovery Falls-Efficacy Scale. The list of items has been developed by a group of community-dwelling older adults who had demonstrated an understanding of near-falls and will be able to articulate the use of balance recovery strategies used in near-fall experiences.
Study: NCT00003389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechlorethamine
Description: given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT02376400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
Study: NCT03441633

Intervention type: DRUG
Intervention: apixaban
Description: current or new medication

Intervention type: DRUG
Intervention: dabigatran
Description: current or new medication

Intervention type: DRUG
Intervention: VKA
Description: current or new medication

Intervention type: DRUG
Intervention: rivaroxaban
Description: current or new medication
Study: NCT02003131

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Trophic factors from umbilical cord mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Trophic factors from umbilical cord mesenchymal stem cells